OptiNose Inc
NASDAQ:OPTN

Watchlist Manager
OptiNose Inc Logo
OptiNose Inc
NASDAQ:OPTN
Watchlist
Price: 9.6 USD -1.13%
Market Cap: $97.2m

Gross Margin

90.8%
Current
Improving
by 2%
vs 3-y average of 88.7%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
90.8%
=
Gross Profit
$71m
/
Revenue
$78.2m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
90.8%
=
Gross Profit
$71m
/
Revenue
$78.2m

Peer Comparison

Country Company Market Cap Gross
Margin
US
OptiNose Inc
NASDAQ:OPTN
96.6m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
571.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
286B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
299.8B USD
Loading...
CH
Novartis AG
SIX:NOVN
226.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
213.9B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
154.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122.8B USD
Loading...

Market Distribution

Higher than 95% of companies in the United States of America
Percentile
95th
Based on 12 729 companies
95th percentile
90.8%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

OptiNose Inc
Glance View

Market Cap
97.2m USD
Industry
Pharmaceuticals

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.

OPTN Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
90.8%
=
Gross Profit
$71m
/
Revenue
$78.2m
What is OptiNose Inc's current Gross Margin?

The current Gross Margin for OptiNose Inc is 90.8%, which is above its 3-year median of 88.7%.

How has Gross Margin changed over time?

Over the last 3 years, OptiNose Inc’s Gross Margin has increased from 87.7% to 90.8%. During this period, it reached a low of 86.8% on Sep 30, 2023 and a high of 90.8% on Jan 31, 2025.

Back to Top